Clinical Trial Update: CPX-351 (Vyxeos™) for Transplant Eligible, Higher Risk Patients With Myelodysplastic Syndrome [Phase 1]

View source ↗

Summary

The Phase 1 trial of Vyxeos (CPX-351) for transplant-eligible, higher-risk myelodysplastic syndrome patients remains active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• Vyxeos (CPX-351)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Myelodysplastic Syndromes | Phase 1 | Status: ACTIVE_NOT_RECRUITING